ILMN Logo

Illumina Inc (ILMN) Stock Forecast & Price Prediction

Live ILMN Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Diagnostics & Research

$100.24

-1.54 (-1.51%)

12 Month Price Forecast For ILMN

$100.24
Current Price
$16.12B
Market Cap
25 Ratings
Buy 13
Hold 10
Sell 2
Wall St Analyst Ratings

Distance to ILMN Price Forecasts

+146.4%
To High Target of $247.00
+43.8%
To Median Target of $144.10
-0.2%
To Low Target of $100.00

ILMN Price Momentum

-9.7%
1 Week Change
-26.4%
1 Month Change
-29.5%
1 Year Change
-25.0%
Year-to-Date Change
-36.0%
From 52W High of $156.66
+3.0%
From 52W Low of $97.36

๐Ÿค” Considering Illumina (ILMN)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 15, 2025 4:19 PM UTC

ILMN Analyst Ratings & Price Targets

Based on our analysis of 34 Wall Street analysts, ILMN has a bullish consensus with a median price target of $144.10 (ranging from $100.00 to $247.00). The overall analyst rating is Buy (7.5/10). Currently trading at $100.24, the median forecast implies a 43.8% upside. This outlook is supported by 13 Buy, 10 Hold, and 2 Sell ratings.

The most optimistic forecast comes from Conor McNamara at RBC Capital, projecting a 146.4% upside. Conversely, the most conservative target is provided by Luke Sergott at Barclays, suggesting a 0.2% downside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

ILMN Analyst Consensus

13
Buy
10
Hold
2
Sell

ILMN Price Target Range

Low
$100.00
Average
$144.10
High
$247.00
Current: $100.24

Latest ILMN Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for ILMN.

Date Firm Analyst Rating Change Price Target
Feb 11, 2025 Morgan Stanley Tejas Savant Equal-Weight Maintains $136.00
Feb 10, 2025 Piper Sandler David Westenberg Overweight Maintains $190.00
Feb 10, 2025 Barclays Luke Sergott Underweight Downgrade $100.00
Feb 7, 2025 RBC Capital Conor McNamara Outperform Maintains $247.00
Feb 7, 2025 Canaccord Genuity Kyle Mikson Hold Maintains $135.00
Feb 7, 2025 Guggenheim Subbu Nambi Buy Maintains $150.00
Feb 3, 2025 Barclays Luke Sergott Equal-Weight Maintains $130.00
Jan 13, 2025 Morgan Stanley Tejas Savant Equal-Weight Maintains $150.00
Dec 11, 2024 Citigroup Patrick Donnelly Neutral Downgrade $165.00
Nov 12, 2024 Morgan Stanley Tejas Savant Equal-Weight Reinstates $156.00
Nov 12, 2024 Stephens & Co. Mason Carrico Overweight Maintains $184.00
Nov 11, 2024 Piper Sandler David Westenberg Overweight Maintains $185.00
Nov 6, 2024 Baird Catherine Ramsey Neutral Maintains $139.00
Nov 5, 2024 TD Cowen Dan Brennan Buy Maintains $177.00
Nov 5, 2024 Citigroup Patrick Donnelly Buy Maintains $190.00
Nov 5, 2024 JP Morgan Julia Qin Neutral Maintains $140.00
Nov 5, 2024 Canaccord Genuity Kyle Mikson Hold Maintains $145.00
Nov 5, 2024 UBS John Sourbeer Neutral Maintains $145.00
Nov 5, 2024 Barclays Luke Sergott Equal-Weight Maintains $145.00
Nov 5, 2024 RBC Capital Conor McNamara Outperform Maintains $254.00

Stocks Similar to Illumina Inc

The following stocks are similar to Illumina based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Illumina Inc (ILMN) Financial Data

Illumina Inc has a market capitalization of $16.12B with a P/E ratio of -13.0x. The company generates $4.37B in trailing twelve-month revenue with a -28.0% profit margin.

Revenue growth is -1.6% quarter-over-quarter, while maintaining an operating margin of -9.6% and return on equity of -30.1%.

Valuation Metrics

Market Cap $16.12B
Enterprise Value $17.28B
P/E Ratio -13.0x
PEG Ratio 22.7x
Price/Sales 3.7x

Growth & Margins

Revenue Growth (YoY) -1.6%
Gross Margin +65.9%
Operating Margin -9.6%
Net Margin -28.0%
EPS Growth -1.6%

Financial Health

Cash/Price Ratio +7.7%
Current Ratio 1.8x
Debt/Equity 110.5x
ROE -30.1%
ROA +2.6%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Illumina Inc logo

Illumina Inc (ILMN) Company Overview

About Illumina Inc

What They Do

Provides genetic and genomic analysis solutions.

Business Model

The company generates revenue through the sale of sequencing and array-based instruments, consumables, and services, targeting a diverse clientele including research centers, hospitals, and biotechnology firms. Its segments, Core Illumina and GRAIL, focus on various genomic solutions, including whole-genome sequencing and cancer detection tests.

Additional Information

Illumina's innovative products, such as the Galleri multi-cancer early detection test, position it at the forefront of genomic technology. With a strong market presence in the U.S., U.K., Singapore, and beyond, and ongoing development of cutting-edge solutions for cancer diagnosis, the company is well-positioned in the rapidly evolving biotech landscape.

Company Information

Sector

Healthcare

Industry

Diagnostics & Research

Employees

10,590

CEO

Mr. Jacob Thaysen Ph.D.

Country

United States

IPO Year

2000

Illumina Inc (ILMN) Latest News & Analysis

ILMN stock latest news image
Quick Summary

Zacks Style Scores can assist investors in selecting strong, market-beating stocks for their portfolios.

Why It Matters

The Zacks Style Scores can guide investors in identifying high-potential stocks, enhancing portfolio performance and increasing the likelihood of achieving market-beating returns.

Source: Zacks Investment Research
Market Sentiment: Positive
ILMN stock latest news image
Quick Summary

Zacks Style Scores provide a tool for investors to identify top-rated stocks aligned with their investment styles.

Why It Matters

Zacks Style Scores provide a systematic approach to identify high-potential stocks, enhancing investment strategies and potentially improving returns.

Source: Zacks Investment Research
Market Sentiment: Positive
ILMN stock latest news image
Quick Summary

Investors in Medical - Biomedical and Genetics stocks are evaluating Illumina (ILMN) and Alnylam Pharmaceuticals (ALNY) for potential value investment opportunities.

Why It Matters

The comparison between Illumina and Alnylam highlights potential investment opportunities in the biomedical sector, influencing stock selection based on value and growth prospects.

Source: Zacks Investment Research
Market Sentiment: Neutral
ILMN stock latest news image
Quick Summary

Illumina shares dropped 15%, while competitors 10X Genomics and Pacific BioSciences fell 18% and 15%, respectively, reflecting a downturn in the gene-sequencing sector.

Why It Matters

Illumina's 15% drop signals potential sector weakness, affecting rivals' valuations. This may prompt investors to reassess their positions in gene-sequencing stocks.

Source: Barrons
Market Sentiment: Negative
ILMN stock latest news image
Quick Summary

Illumina (ILMN) shares fell nearly 6% on Monday due to a downgrade by an analyst, despite the S&P 500 rising 0.7%. This marks the second consecutive day of declines for the stock.

Why It Matters

Illumina's stock decline amid a broader market rise signals potential investor concern over its fundamentals, impacting sentiment and future performance expectations.

Source: The Motley Fool
Market Sentiment: Negative
ILMN stock latest news image
Quick Summary

Illumina's international revenue performance influences Wall Street analysts' forecasts, impacting future stock prospects and investor sentiment.

Why It Matters

Illumina's international revenue impacts growth forecasts and market sentiment, influencing stock performance and investment strategies among analysts.

Source: Zacks Investment Research
Market Sentiment: Negative

Frequently Asked Questions About ILMN Stock

What is Illumina Inc's (ILMN) stock forecast for 2025?

Based on our analysis of 34 Wall Street analysts, Illumina Inc (ILMN) has a median price target of $144.10. The highest price target is $247.00 and the lowest is $100.00.

Is ILMN stock a good investment in 2025?

According to current analyst ratings, ILMN has 13 Buy ratings, 10 Hold ratings, and 2 Sell ratings. The stock is currently trading at $100.24. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for ILMN stock?

Wall Street analysts predict ILMN stock could reach $144.10 in the next 12 months. This represents a 43.8% increase from the current price of $100.24. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Illumina Inc's business model?

The company generates revenue through the sale of sequencing and array-based instruments, consumables, and services, targeting a diverse clientele including research centers, hospitals, and biotechnology firms. Its segments, Core Illumina and GRAIL, focus on various genomic solutions, including whole-genome sequencing and cancer detection tests.

What is the highest forecasted price for ILMN Illumina Inc?

The highest price target for ILMN is $247.00 from Conor McNamara at RBC Capital, which represents a 146.4% increase from the current price of $100.24.

What is the lowest forecasted price for ILMN Illumina Inc?

The lowest price target for ILMN is $100.00 from Luke Sergott at Barclays, which represents a -0.2% decrease from the current price of $100.24.

What is the overall ILMN consensus from analysts for Illumina Inc?

The overall analyst consensus for ILMN is bullish. Out of 34 Wall Street analysts, 13 rate it as Buy, 10 as Hold, and 2 as Sell, with a median price target of $144.10.

How accurate are ILMN stock price projections?

Stock price projections, including those for Illumina Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.